Why Batteries, Bauxite and Magnets Are Becoming Defence Priorities
14 August 2026.Washington targets critical material dependencies across batteries, bauxite and magnets
Washington targets critical material dependencies across batteries, bauxite and magnets
Moderna’s flu approval tests whether mRNA can deliver commercial scale
Washington targets missile and drone bottlenecks across critical defence supply chains
Drug delivery is reshaping biologics development, manufacturing, access and competition
Washington targets missile-supply bottlenecks to expand PAC-3 and THAAD production
Ageing reshapes pharma portfolios as access, evidence and delivery determine growth
Canada joins GCAP as Britain accelerates its next-generation combat-air strategy
Policy, platforms and manufacturing are reshaping global vaccine market opportunities
US reforms target faster production, secure supply chains, lower costs
Manufacturing readiness now determines which cell and gene therapies scale
GCAP contract tests allied ambition, industrial capacity and combat-air delivery
UK drone investment tests hybrid force design, funding and delivery
Healthcare moves home as pharma’s commercial model shifts toward patients
Patient persistence is becoming pharma’s next growth test after launch
Low-cost drones force faster procurement and resilient defence supply chains
Prevention-led pharma growth depends on earlier intervention, access and scale
Submarine delays push allies towards faster, riskier undersea autonomy bets
Healthcare growth is shifting from standard treatments to personalised patient strategies
Women’s health trials enter a more evidence-led, higher-value growth phase
AUKUS faces an industrial test as delivery risks intensify